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Risk Factors for Cerebral Edema in Children 
with Diabetic Ketoacidosis
To the Editor: The study by Glaser et al. (Jan. 25 issue)1
identified risk factors for the development of symptomatic
cerebral edema in children with diabetic ketoacidosis. Of
the 61 children in whom symptomatic cerebral edema de-
veloped, 57 percent recovered completely, 21 percent had
permanent neurologic damage, and 21 percent died. The
investigators did not identify the risk factors for death from
cerebral herniation or for permanent neurologic damage.
It would be clinically relevant to compare the children who
died or had permanent neurologic damage with those who
did not have symptomatic cerebral edema or who had symp-
tomatic cerebral edema but recovered completely.
The authors conclude that the rate of fluid administra-
tion and the tonicity of the fluid that was administered,
when analyzed separately, were not related to the risk of
cerebral edema. However, they did not evaluate whether the
use of hypotonic fluid, when administered at a high rate,
was a risk factor for cerebral edema. It is possible that both
of these factors are necessary to increase the risk of cere-
bral edema. Finally, the authors identified three children who
had cerebral edema before the initiation of therapy. Did
these children receive excessive oral rehydration with hy-
potonic fluid (such as water) at home, before their presen-
tation at the hospital?
BASSAM M. GEBARA, M.D.
William Beaumont Hospital
Royal Oak, MI 48073
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The authors reply:
To the Editor: Dr. Gebara raises several issues that merit
responses. First, limiting the cerebral-edema group to pa-
tients with adverse outcomes would be relevant only if inter-
ventions for the treatment of cerebral edema were ineffec-
tive. Although there is limited information about therapy for
cerebral edema in children with diabetic ketoacidosis, case
reports suggest that prompt initiation of hyperosmolar ther-
apy may be beneficial.1,2 We therefore cannot assume that
the children who survived without sequelae had a less severe
form of the disease than those who had adverse outcomes.
Second, although there are theoretical reasons why rap-
id administration of hypotonic fluids might contribute to
cerebral edema, neither the rate of fluid administration nor
the rate of sodium administration was significantly associ-
ated with cerebral edema in the patients we studied. In ad-
dition, in a subanalysis that we conducted, an interaction
term combining the rates of fluid and sodium administra-
tion was not significantly associated with cerebral edema.
We recommend that physicians caring for children with di-
abetic ketoacidosis administer rehydration therapy to these
patients at moderate rates and that isotonic fluids be used
for the initial several hours.
Finally, we do not know whether children who had cer-
ebral edema before in-hospital therapy for diabetic ketoac-
idosis ingested excess hypotonic fluid at home. Most children
with severe diabetic ketoacidosis, however, have a history
of persistent vomiting and present with gastrointestinal il-
eus. It is therefore unlikely that they could both ingest and
absorb substantial quantities of fluid at the same time.
NICOLE GLASER, M.D.
NATHAN KUPPERMANN, M.D., M.P.H.
University of California, Davis, School of Medicine
Davis, CA 95616
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Case 4-2001: Acute Sarcoidosis
To the Editor: The February 8 Case Record1 involves a
patient with Löfgren’s syndrome. In his discussion of the
case, Dr. Bates does not sufficiently emphasize the impor-
tance of the recognition of periarticular ankle inflamma-
tion as a particular presenting sign of acute sarcoidosis. In
the Nordic countries and Spain, Löfgren’s syndrome is the
most common form of the disease and frequently starts with
periarticular ankle inflammation. In our series of 186 white
patients with Löfgren’s syndrome, 35 (19 percent) present-
ed with periarticular ankle inflammation alone and 46 (25
percent) had periarticular ankle inflammation in associa-
tion with erythema nodosum.2
Periarticular ankle inflammation is an acute inflamma-
tion of the tissues around the ankles without true arthritis.
The typical lesions of erythema nodosum may be absent or
may appear concomitantly with periarticular ankle inflam-
mation, or a few days later. Arthrocentesis is ineffective, and
biopsy of the inflamed skin shows nonspecific panniculitis.
The accompanying clinical and radiologic findings and
final outcome are so similar to those of classic Löfgren’s
syndrome that this condition is considered to be a variant
of Löfgren’s syndrome, even in the absence of erythema
nodosum.3 The diagnosis of sarcoidosis should be strongly
considered in patients who present with periarticular ankle
inflammation, whether or not they have associated erythe-
ma nodosum, and a chest radiograph should be obtained
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To the Editor: Dr. Bates appropriately cites Willan as pro-
viding the first description of erythema nodosum in the
medical literature, in 1798. However, Leopold Mozart,
Wolfgang’s father, should receive some credit for his earlier
and apt description of that syndrome. In a letter to his
wife dated October 30, 1762, Leopold describes his ailing
son in the following manner:
As he was going to bed, he complained a good deal of
his backside and his hips. When he got into bed, I ex-
amined the places where he said he had pain and found
a few spots as large as a kreutzer [a small Austrian coin],
very red and slightly raised and painful to the touch. But
they were only on his shins, on both elbows, and a few
on his posterior; altogether there were very few.1
Leopold’s description of the evolution of these lesions
provides convincing evidence that he should share credit
for documenting this important clinical syndrome.
ROBERT B. HOWE, M.D.
University of Minnesota Medical School
Minneapolis, MN 55455
1. Anderson E. The letters of Mozart and his family. New York: Norton, 
1985.
The authors reply:
To the Editor: Mañá and colleagues appropriately em-
phasize the importance of symmetric periarticular ankle
inflammation as a presenting sign of acute sarcoidosis. The
distinction between this syndrome and symmetric poly-
arthritis is subtle but important. Both can provide important
clues with respect to the onset of acute sarcoidosis.
Howe describes a fascinating historical reference to the
early recognition of erythema nodosum. We were unaware
of this citation, which predates Willan’s description of erythe-
ma nodosum in the medical literature in 1798. We doubt
that Willan would mind sharing this distinction with Wolf-
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Review of The Adonis Complex
To the Editor: We question the scientific basis for several
statements in Handelsman’s recent review of our book,
The Adonis Complex (Jan. 11 issue).1 Handelsman dismiss-
es anabolic-steroid–induced hypomanic syndrome (some-
times called “roid rage”) as “street folklore” and “an excuse
for bad behavior,” a claim that contradicts the findings of
three placebo-controlled, double-blind studies and numer-
ous controlled field studies.2,3 He also dismisses as “an un-
substantiated claim” our suggestion that there is a natural
limit to the muscularity that lean men can attain without
steroids, despite the fact that our hypothesis is based on a
peer-reviewed study of 157 athletes4 that has never, to our
knowledge, been challenged in the subsequent literature.3
If Handelsman or others possess contrary evidence, we
would urge them to publish it for scientific inspection.
Handelsman also implies that we have neglected the pos-
sibility that male body-image disorders might be “merely
a variant of obsessive–compulsive disorder.” Yet we propose
precisely this hypothesis in our book and in our published
scientific papers.5 More generally, Handelsman states that
our book provides “no specific bibliography, making it hard
to examine its scientific background.” The Adonis Complex,
however, cites more than 290 publications, including 200
peer-reviewed studies, more than 40 of which are from our
own laboratories.
We also question the reviewer’s characterization of our
patients. Body-image disorders are recognized diagnostic
entities that are sometimes associated with serious morbid-
ity and even mortality. Calling these patients “pathetic men”
with “narcissistic self-absorption” who are engaged in a
“comic-book satire” trivializes their disabling and treatable
psychiatric conditions.
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Dr. Handelsman replies:
To the Editor: Reviewing a review starts a downward spiral.
It is a meager defense against a critique of deficient scien-
tific rigor in an approximately 300-page book to complain
that a short review lacks scientific details. Whether scatter-
ing references among footnotes regardless of their quality
constitutes a specific bibliography or not, it hinders the
evaluation of the scientific validity of assertions — a task the
book’s popular approach often makes necessary. Semantic
quibbles over how to describe the behavior of men enslaved
by destructive obsessions do not warrant an argument.
The new law of nature on body composition that the
authors claim to have discovered relies on evidence such as
guessing body weight and height from fan-magazine pho-
tos. Does a 1.0-m-tall dwarf weighing 40 kg defy a law of
nature or merely an extravagant claim? The onus of scien-
tific proof is on the proponents and requires independent
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